Last reviewed · How we verify
Omaveloxolone Capsules, 150 mg — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Omaveloxolone Capsules, 150 mg (Omaveloxolone Capsules, 150 mg) — Biogen.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Omaveloxolone Capsules, 150 mg TARGET | Omaveloxolone Capsules, 150 mg | Biogen | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Omaveloxolone Capsules, 150 mg CI watch — RSS
- Omaveloxolone Capsules, 150 mg CI watch — Atom
- Omaveloxolone Capsules, 150 mg CI watch — JSON
- Omaveloxolone Capsules, 150 mg alone — RSS
Cite this brief
Drug Landscape (2026). Omaveloxolone Capsules, 150 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/omaveloxolone-capsules-150-mg. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab